Tumor genetics matter because they affect how easily the immune system can recognize colorectal cancer. Tumors with defective DNA mismatch repair (dMMR) often accumulate mutations that produce abnormal proteins. Those proteins can make cancer cells easier for immune cells to detect, which helps explain why dMMR or microsatellite instability-high (MSI-H) tumors are more likely to respond to checkpoint inhibitors. Most mismatch repair-proficient (pMMR) or microsatellite-stable (MSS) tumors respond poorly to these drugs alone.[1]
Checkpoint inhibitors are one form of cancer immunotherapy. Drugs that block PD-1 or CTLA-4 release signals that restrain immune activity; they do not repair the tumor’s genes.[2]
Which Tumors Are More Likely to Respond?
About 15% of colorectal cancers are MSI-H/dMMR, compared with roughly 4%–5% of metastatic cases. These are population estimates, not treatment success rates.
| Tumor finding | Treatment implications |
|---|---|
| MSI-H or dMMR | Eligible patients with unresectable or metastatic cancer may receive checkpoint inhibitors as their first systemic treatment. A positive result does not guarantee a response. |
| MSS or pMMR | Checkpoint inhibitor monotherapy usually offers limited benefit. Surgery, chemotherapy, and targeted treatments remain options, depending on stage and other molecular findings. |
| Specific POLE/POLD1 variants | Some variants disrupt DNA proofreading and produce highly mutated tumors, including some classified as MSS. These require specialist interpretation. |
The POLE/POLD1 exception concerns variants that cause proofreading deficiency—not every change reported in either gene. Clinical evidence supports sensitivity to checkpoint inhibitors in this rare subgroup, but a gene name alone cannot guide treatment.[3]
What the Treatment Data Show
| Study | Comparison | Result |
|---|---|---|
| KEYNOTE-177: 307 patients without previous systemic treatment for metastatic disease | Pembrolizumab versus chemotherapy, with selected targeted drugs permitted | Median progression-free survival in the initial analysis was 16.5 versus 8.2 months.[4] |
| CheckMate-8HW: 582 patients in the centrally confirmed analysis across treatment lines | Nivolumab plus ipilimumab versus nivolumab alone | The FDA’s 2025 analysis reported objective response rates of 71% versus 58%.[5] |
16.5 months is not a life expectancy, and 71% is not a cure rate. Progression-free survival measures time before disease progression or death. Objective response measures tumor shrinkage that meets the study’s criteria.
The trials do not directly compare pembrolizumab with nivolumab plus ipilimumab. Their results also cannot be applied to NK-cell therapy, which uses a different treatment approach and requires its own evidence. Drug availability and approved uses vary by country.
Which Tests Are Needed?
Check the pathology report for MMR protein staining or an MSI result. These tests often use tissue already collected during a biopsy or surgery. A large sequencing panel is not always necessary solely to establish MMR/MSI status.[6]
| Test | What it assesses |
|---|---|
| MMR immunohistochemistry | Expression of four repair proteins: MLH1, PMS2, MSH2, and MSH6 |
| MSI testing by PCR | Instability in selected repetitive DNA sequences |
| Validated next-generation sequencing | MSI status, where supported by the panel, and other molecular changes that may guide treatment |
dMMR and MSI-H usually agree, but they describe different findings. If one test reports dMMR and another reports MSS, the pathology team should review the sample and methods. Both tests do not have to be positive for treatment to be considered. An inconclusive result, however, establishes neither eligibility nor ineligibility.
PD-L1 positivity or high tumor mutational burden cannot replace MMR/MSI testing. RAS, BRAF, and HER2 results may guide targeted treatment, but they are not interchangeable with these immunotherapy markers.
Can Rectal Cancer Patients Avoid Surgery?
In a phase 2 study published in 2025, all 49 patients with dMMR rectal cancer who completed dostarlimab treatment achieved a clinical complete response. The study’s assessments found no detectable tumor. This was a selected patient group, not a 100% success rate for rectal cancer generally.[7]
Clinical complete response does not establish permanent cure. Patients managed without surgery need specialist follow-up with rectal examinations, endoscopy, and pelvic MRI. Persistent or returning cancer may require surgery. The result cannot be used to justify omitting surgery for operable colon cancer.
Does dMMR Mean the Cancer Is Hereditary?
No. Some dMMR cancers are associated with Lynch syndrome; others develop through non-inherited changes. Loss of MLH1 and PMS2 expression may prompt testing for MLH1 promoter methylation or BRAF V600E. Doctors use these findings alongside age at diagnosis and personal and family cancer history to decide whether germline testing is needed.[8]
A tumor test cannot establish whether a patient’s children carry the same variant. Assessing inherited risk may require a separate test using blood or saliva.
Response and Side Effects Need Monitoring
Even MSI-H/dMMR tumors may fail to respond or develop resistance. Doctors assess treatment with scans, symptoms, and physical function—not CEA alone. Tumor growth accompanied by worsening pain, bowel obstruction symptoms, or declining strength needs prompt review rather than an assumption of pseudoprogression.
Checkpoint inhibitors can also cause inflammation in healthy organs, during treatment or after it ends. Tell the care team about autoimmune disease, an organ transplant, and immune-suppressing medicines before treatment. Report these symptoms promptly:[9]
- Diarrhea, bloody stools, or abdominal pain: possible bowel inflammation.
- New cough or breathlessness: possible lung inflammation.
- Yellowing skin or eyes, or dark urine: possible liver injury.
- Marked fatigue, dizziness, or unusual thirst: possible hormone-related problems.
Seek emergency care for severe breathing difficulty, chest pain, confusion, or severe dehydration. Do not start or stop steroids or cancer medicines without medical advice.
What to Ask at Your Appointment
- No MMR/MSI result: Can the existing biopsy or surgical sample be tested?
- MSI-H/dMMR: Does my stage support immunotherapy, and what would favor one drug over a combination?
- MSS/pMMR: Which established treatments remain available? If immunotherapy is proposed, what molecular finding or clinical trial supports it?
This article provides general health information and does not replace individual medical advice.